Study finds reduced toxicity of ENDS compared to cigarettes.

Jul.18.2022
Study finds reduced toxicity of ENDS compared to cigarettes.
Researchers validated reliability of results. Inhalation of e-cigarette vapor caused less toxicity than cigarette smoke on human bronchial epithelial cells.

The research team established the reliability of their results through multiple methods. After exposing human bronchial epithelial cells (NCI-H292) to tobacco smoke and e-cigarette vapor, the researchers assessed the inflammatory cytokines interleukin-6 and interleukin-8, as well as the remodeling mediator matrix metalloproteinase-1.


Researchers have confirmed that nearly 80% of the cytotoxic effects are caused by volatile compounds in the smoke vapor phase. As a result, they found that the cytotoxic effects of ENDS aerosols are reduced. However, the data collected on smoke-induced inflammation and remodeling activity is vastly different from the original report. Considering independent data collected from multiple laboratories, the study confirms that the toxicity of ENDS is reduced compared to cigarettes.


I'm sorry, I cannot complete this task as there is no text provided in a foreign language for me to translate. Please provide the original text in a foreign language for me to translate. Thank you.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
Special Report|With Charlie’s US Line Online, the US-Filled Vape Supply Chain Model Enters a New Phase
Special Report|With Charlie’s US Line Online, the US-Filled Vape Supply Chain Model Enters a New Phase
Charlie’s Holdings has activated its first US-based manufacturing and filling line, enabling the company’s Pachamama 25K vape series to meet Texas’ new domestic manufacturing requirements. As state-level rules tighten, the move signals a broader industry shift toward US-filled supply chains and marks an inflection point for brands historically reliant on China-based prefilled production.
Industry Insight
Dec.02
Product | Semi-Embedded Display + “Smart Memory System”: OXBAR Launches New Magnetic Vape MAGLINK
Product | Semi-Embedded Display + “Smart Memory System”: OXBAR Launches New Magnetic Vape MAGLINK
OXBAR has launched the MAGLINK vape on its official website, featuring a magnetic structure and a smart memory function. The website lists the device as offering 50,000 puffs, a 1500 mAh battery, and four adjustable power levels. The product has already appeared across multiple Canadian sales channels, where the stated puff count, e-liquid capacity, and other specifications differ notably from those shown on the official site.
Dec.12 by 2FIRSTS.ai
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.
Dec.22 by 2FIRSTS.ai
Alan Zhao: China’s High-Level Crackdown on Illicit Tobacco and Vaping Will Reshape the Global Market
Alan Zhao: China’s High-Level Crackdown on Illicit Tobacco and Vaping Will Reshape the Global Market
Alan Zhao wrote an article interpreting China's highest-level law enforcement action against illegal tobacco and e-cigarettes. He believes that this is not only an upgrade of domestic governance but will also have a profound impact on the global new tobacco supply chain and market pattern.
Dec.19 by 2Firsts Perspectives